Industry Educational Resources

The content linked to this page is not developed by AACVPR but by commercial entities. The materials have been vetted by AACVPR to determine that they are educational in nature. The appearance of this content does not serve as a warranty, endorsement or approval of the subject matter. AACVPR does not make any representation as to the accuracy or suitability of the content provided, and disclaims responsibility for any injury to persons or property resulting from information provided. If you have a question about the material, or experiencing a technology issue, please contact the commercial entity directly.

Lung Biotechnology VSP COPD: PERFECT Time to Uncover the Veil of PH

The PERFECT clinical study is to evaluate the efficacy and safety of Treprostinil for inhalation (Tyvaso®), in patients who have developed pulmonary hypertension due to COPD.

The PERFECT study is currently enrolling participants. This is a phase 3, placebo-controlled study with 25 weeks duration of treatment. The crossover design allows all patients to receive the active drug for 12 weeks during the study. Upon the completion of the study, the patients will be eligible to enroll in an open-label extension, where they will have an opportunity to receive Tyvaso® for an extended period of time.

Importantly, there are currently no available pharmacological therapies for Pulmonary Hypertension due to COPD, and treatments for COPD such as bronchodilators and steroids do not impact PH. Treprostinil for inhalation (Tyvaso®) is approved by the FDA for Pulmonary Arterial Hypertension (WHO group 1) and Pulmonary Hypertension due to Interstitial Pulmonary Disease. The PERFECT study aims to provide the first therapy for patients who suffer from Pulmonary Hypertension due to COPD.